Literature DB >> 30656530

Intramedullary spinal cord metastases: an institutional review of survival and outcomes.

Anshit Goyal1,2, Yagiz Yolcu1,2, Panagiotis Kerezoudis1,2, Mohammed Ali Alvi1,2, William E Krauss2, Mohamad Bydon3,4.   

Abstract

INTRODUCTION: Intramedullary spinal cord metastases (ISCMs) are rare lesions affecting the spinal cord in patients with disseminated malignancy. Today, due to increased survival, these lesions are more frequently diagnosed. Literature on survival and neurologic outcomes is sparse. Herein, we describe a single institutional case series on ISCMs reported to date in the English literature.
METHODS: We retrospectively analyzed the medical records of patients diagnosed with intramedullary metastatic lesions at our institution between 1997 and 2016. We analyzed different approaches to management and factors influencing survival and neurologic outcomes.
RESULTS: A total of 70 patients (86 lesions) were analyzed. Most lesions were found in thoracic spinal cord (50%) followed by cervical (34%) and conus medullaris (14%). Mean age at diagnosis was 55.6 ± 10.6 years with 60% (n = 42) being females. Median survival was 104.5 days (range 1-888 days). Twenty-three patients (33%) received conservative management, 39 (56%) received palliative radiotherapy, whereas 8 (11%) underwent surgery with one patient receiving only a biopsy. Age, sex, presence of concomitant brain and other systemic metastasis didn't influence survival. Patients with solitary metastases had longer survival compared to multiple lesions (3.6 vs. 2.2 months, p = 0.01). In patients with solitary lesions without brain metastasis, surgical resection was associated with significantly longer survival (6 months vs. 3 months, p = 0.02).
CONCLUSION: The overall survival in patients with intramedullary metastasis remains poor. Surgical management may contribute to improved survival and neurologic outcomes in selected patients. Intramedullary metastasis may have a greater role on overall survival compared to systemic metastatic burden.

Entities:  

Keywords:  Conservative treatment; Intramedullary; Metastases; Outcomes; Spinal cord; Spinal cord neoplasms; Spine; Survival

Mesh:

Year:  2019        PMID: 30656530     DOI: 10.1007/s11060-019-03105-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  5 in total

1.  Surgical Treatment of Intra- and Juxtamedullary Spinal Cord Tumors: A Population Based Observational Cohort Study.

Authors:  Oscar Persson; Alexander Fletcher-Sandersjöö; Gustav Burström; Erik Edström; Adrian Elmi-Terander
Journal:  Front Neurol       Date:  2019-07-26       Impact factor: 4.003

2.  Image-Guided Robotic Radiosurgery for the Management of Intramedullary Spinal Cord Metastases-A Multicenter Experience.

Authors:  Felix Ehret; Carolin Senger; Markus Kufeld; Christoph Fürweger; Melina Kord; Alfred Haidenberger; Paul Windisch; Daniel Rueß; David Kaul; Maximilian Ruge; Christian Schichor; Jörg-Christian Tonn; Alexander Muacevic
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

3.  Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.

Authors:  Marion Tonneau; Raphaëlle Mouttet-Audouard; Florence Le Tinier; Xavier Mirabel; David Pasquier
Journal:  BMC Cancer       Date:  2021-10-30       Impact factor: 4.430

4.  Clinical Features, Treatments, and Prognosis of Intramedullary Spinal Cord Metastases From Lung Cancer: A Case Series and Systematic Review.

Authors:  Liang Wu; Li'ao Wang; Jun Yang; Wenqing Jia; Yulun Xu
Journal:  Neurospine       Date:  2022-02-03

5.  Correlation of Intraoperative Neurophysiological Parameters and Outcomes in Patients with Intramedullary Tumors.

Authors:  Leonardo Gilmone Ruschel; Afonso Aragão; Matheus Fernandes de Oliveira; Jerônimo Buzetti Milano; Mauricio Coelho Neto; Ricardo Ramina
Journal:  Asian J Neurosurg       Date:  2021-05-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.